Immunisation against αiibβ3 and αvβ3 in a type 1 variant of glanzmann’s thrombasthenia caused by a missense mutation Gly540Asp on β3

Thrombosis and Haemostasis

Volumn 116, Issue 2, 2016, Pages 262-271

  Wihadmadyatami, Hevi ^a,b   Röder, Lida ^a   Berghöfer, Heike ^a   Bein, Gregor ^a   Heidinger, Kathrin ^c   Sachs, Ulrich J ^a,c   Santoso, Sentot ^a  

^a JUSTUS LIEBIG UNIVERSITY   (Germany)

^b GADJAH MADA UNIVERSITY   (Indonesia)

^c UNIVERSITY HOSPITAL GIESSEN   (Germany)

Author keywords

Av 33; Glanzmann s thrombasthenia; Isoimmuni sation; Platelet function defect

Indexed keywords

ADENOSINE DIPHOSPHATE; ADRENALIN; ALLOANTIBODY; ALPHA2B BETA3 INTEGRIN; ARACHIDONIC ACID; BETA3 INTEGRIN; COLLAGEN; GLYCOPROTEIN; MONOCLONAL ANTIBODY; RISTOCETIN; UNCLASSIFIED DRUG; VITRONECTIN RECEPTOR; ALPHA2 INTEGRIN; FIBRINOGEN RECEPTOR; ITGA2B PROTEIN, HUMAN; ITGB3 PROTEIN, HUMAN; RECOMBINANT PROTEIN;

AGED; ANIMAL CELL; ANTIBODY PRODUCTION; APOPTOSIS ASSAY; ARTICLE; BRAIN HEMORRHAGE; CASE REPORT; CELL ADHESION ASSAY; CHO CELL LINE; CONTROLLED STUDY; DNA SEQUENCE; ENDOTHELIUM CELL; EXPRESSION VECTOR; FLOW CYTOMETRY; GENE EXPRESSION; GENETIC TRANSFECTION; GLANZMANN DISEASE; HUMAN; IDIOPATHIC THROMBOCYTOPENIC PURPURA; IMMUNIZATION; IMMUNOBLOTTING; IMMUNOPRECIPITATION; MALE; MISSENSE MUTATION; NONHUMAN; PARTIAL GASTRECTOMY; PLATELET AGGREGATION ASSAY; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; THROMBOCYTE RICH PLASMA; AMINO ACID SUBSTITUTION; ANIMAL; BLOOD; CHEMISTRY; CRICETULUS; DNA MUTATIONAL ANALYSIS; GENETICS; IMMUNOLOGY; MOLECULAR MODEL; PROTEIN DOMAIN; THROMBOCYTE;

AGED; AMINO ACID SUBSTITUTION; ANIMALS; BLOOD PLATELETS; CHO CELLS; CRICETULUS; DNA MUTATIONAL ANALYSIS; HUMANS; IMMUNIZATION; INTEGRIN ALPHA2; INTEGRIN ALPHAVBETA3; INTEGRIN BETA3; ISOANTIBODIES; MALE; MODELS, MOLECULAR; MUTATION, MISSENSE; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; PROTEIN DOMAINS; RECOMBINANT PROTEINS; THROMBASTHENIA; TRANSFECTION;

EID: 84980410210     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH15-12-0982     Document Type: Article

References (32)

1. Nurden AT, Fiore M, Nurden P, et al. Glanzmann thrombasthenia: a review of ITGA2B and ITGB3 defects with emphasis on variants, phenotypic variability, and mouse models. Blood 2011; 118: 5996-6005.
2. Sandrock K, Halimeh S, Wiegering V, et al. Homozygous point mutations in platelet glycoprotein ITGA2B gene as cause of Glanzmann thrombasthenia in 2 families B. Klin Padiatr 2012; 224: 174-178.
3. Fiore M, Firah N, Pillois X, et al. Natural history of platelet antibody formation against aiibp3 in a french cohort of glanzmann thrombasthenia patients. Haemophilia 2012; 18: 201-209.
4. Tokgoz H, Ozkan TD, Caliskan U, et al. Novel mutations of integrin aIIb and β3 genes in Turkish children with Glanzmann’s thrombasthenia. Platelets 2015; 26: 779-782.
5. Franchini M, Favaloro EJ, Lippi G. Glanzmann thrombasthenia: an update. Clin Chim Acta 2010; 411: 1-2.
6. Nurden AT. Glanzmann thrombasthenia. Orphanet J Rare Dis 2006; 6: 1-10.
7. Poon MC, Zotz R, Minno GD, et al. Glanzmann’s thrombasthenia treatment: a prospective observational registry on the use of recombinant human activated factor VII and other hemostatic agents. Semin Hematol 2006; 43 (1 Suppl 1): S33-36.
8. Kashiwagi H, Kiyomizu K, Kamae T, et al. Molecular analysis of a patient with type I Glanzmann thrombasthenia and clinical impact of the presence of anti-aIIbβ3 alloantibodies. Int J Hematol 2011; 93: 106-111.
9. Santoro C, Rago A, Biondo F, et al. Prevalence of allo-immunisation anti-HLA and anti-integrin aIIbp3 in Glanzmann Thromboasthenia patients. Haemophilia 2010; 16: 805-812.
10. Fiore M, Firah N, Pillois X, et al. Natural history of platelet antibody formation against aIIbp3 in a French cohort of Glanzmann thrombasthenia patients. Haemophilia 2012;18: e201-e209.
11. Leticee N, Kaplan C, Lemery D. Pregnancy in mother with Glanzmann’s thrombasthenia and isoantibody against GPIIb-IIIa: Is there a foetal risk? Eur J Obstet Gynecol Reprod Biol 2005; 121: 139-142.
12. Siddiq S, Clark A, Mumford A. A systematic review of the management and outcomes of pregnancy in Glanzmann thrombasthenia. Haemophilia 2011; 17: e858-869.
13. Grimaldi CM, Chen F, Wu C, et al. Glycoprotein IIb Leu214Pro mutation produces glanzmann thrombasthenia with both quantitative and qualitative abnormalities in GPIIb/IIIa. Blood 1998; 91: 1562-1571.
14. Santoso S, Zimmermann U, Neppert J, et al. Receptor patching and capping of platelet membranes induced by monoclonal antibodies. Blood 1986; 67: 343-349.
15. Horton MA, Lewis D, McNulty K, et al. Monoclonal antibodies to osteoclasto-mas βgiant cell bone tumors: definition of osteoclast-specific cellular antigens. Cancer Res 1985; 45: 5663-5669.
16. Kamata T, Handa M, Takakuwa S, et al. Epitope Mapping for Monoclonal Antibody Reveals the Activation Mechanism for avβ3 Integrin. PLoS One 2013; 8: e66096.
17. Santoso S, Kiefel V, Richter IG, et al. A functional platelet fibrinogen receptor with a deletion in the cysteine-rich repeat region of the betaβ3 integrin: the Oeβa alloantigen in neonatal alloimmune thrombocytopenia. Blood 2002; 99: 1205-1214.
18. Peterson JA, Gitter ML, Kanack A, et al. New low frequency platelet glycopro-tein polymorphisms associated with neonatal alloimmune thrombocytopenia. Transfusion 2010; 50: 324-333.
19. Kiefel V, Santoso S, Weisheit M, et al. Monoclonal antibody-specific immobilisation of platelet antigens βMAIPA: a new tool for the identification of platelet-reactive antibodies. Blood 1987; 70: 1722-1726.
20. Tamura K, Stecher G, Peterson D, et al. MEGA6: Molecular Evolutionary Genetics Analysis Version 6.0. Mol Biol Evol 2013; 30: 2725-2729
21. Calvete JJ. On the structure and function of platelet integrin alpha IIb beta 3, the fibrinogen receptor. Proc Soc Exp Biol Med 1995; 208: 346-360.
22. Newman PJ, Seligsohn U, Lyman S, et al. The molecular genetic basis of Glanz-mann thrombasthenia in the Iraqi-Jewish and Arab populations in Israel. Proc Natl Acad Sci USA 1991; 88: 3160-3164.
23. Ruan J, Schmugge M, Kenneth JC, et al. Homozygous Cys542-->Arg substitution in GPIIIa in a Swiss patient with type I Glanzmann’s thrombasthenia. Br J Haematol 1999; 105: 523-531.
24. Nurden AT, Pillois X, Fiore M, et al. Expanding the mutation spectrum affecting aIIbp3 integrin in glanzmann thrombasthenia: screening of the ITGA2B and ITGB3 genes in large international cohort. Hum Mutat 2015; 36: 548-561.
25. Ambo H, Kamata T, Handa M, et al. Novel point mutations in the alphaIIb sub-unit (Phe289-->Ser, Glu324-->Lys and Gln747-->Pro) causing thrombasthenic phenotypes in four Japanese patients. Br J Haematol 1998; 102: 829-840.
26. Sachs UJ. Fetal/neonatal alloimmune thrombocytopenia. Thromb Res 2013; 131 (Suppl 1): S42-46.
27. Boval B, Bellucci S, Boyer-Neumann C, et al. Glanzmann’s thrombasthenia and pregnancy: clinical observations and management of four affected women. Thromb Haemost 2001; 86: P1154 (Abstract).
28. Sundqvist SB, Nilsson IM, Svanberg L, et al. Pregnancy and parturition in a patient with severe Glanzmann’s thrombasthenia. Scand J Haematol 1981; 27: 159-164.
29. Ito K, Yoshida H, Hatoyama H, et al. Antibody removal therapy used successfully at delivery of a pregnant patient with Glanzmann’s thrombasthenia and multiple anti-platelet antibodies. Vox Sang 1991; 61: 40-46.
30. Tadokoro S, Tomiyama Y, Honda S, et al. Missense mutations in the β3 subunit have a different impact on the expression and function between aIIbβ3 and avβ3. Blood 2002; 99:931-938.
31. Mor-cohen R, Rosenberg N, Einav Y, et al. Unique disulfide bonds in epidermal growth factor EGF domains of b3 affect structure and function of aIIbβ3 and avβ3 integrin in different manner. J Biol Chem 2012; 287: 8878-8891.
32. Zhu J, Luo BH, Xiao T, et al. Structure of a complete integrin ectodomain in a physiologic resting state and activation and deactivation by applied forces. Mol Cell 2008; 32: 849-861.